Chris Zambataro
About Chris Zambataro
Chris Zambataro is a Senior Scientist at Bristol Myers Squibb with extensive experience in drug discovery and development, particularly in the field of cardiology.
Current Position at Bristol Myers Squibb
Chris Zambataro holds the position of Senior Scientist at Bristol Myers Squibb. In this role, he leverages his extensive background in drug discovery and translational research to contribute to the development of cutting-edge pharmaceutical solutions. His expertise in in vitro techniques bolsters the company's efforts in bringing new treatments to market.
Previous Roles and Experience
Chris Zambataro has a robust history of roles in various research and pharmaceutical companies. Notably, he was a Scientist II at Edgewise Therapeutics in 2022, a Scientist I at Bristol Myers Squibb in 2021, and a Senior Research Associate II at MyoKardia from 2018 to 2021. His earlier roles include working as a Lab Manager/Research Associate II at the Buck Institute for Age Research and as an intern at the University of Skövde in Sweden.
Educational Background in Molecular Biology
Chris Zambataro achieved both his Bachelor's and Master's degrees in Molecular Biology from Dominican University of California. He completed his undergraduate studies from 2005 to 2009 and earned his Master's degree from 2010 to 2012. His academic background laid a strong foundation for his subsequent career in scientific research and drug discovery.
Notable Contributions to Drug Discovery
Chris played a key role in the discovery team for Mavacamten (CAMZYOS), which received FDA approval in 2022. Additionally, he contributed significantly to the development of Danicamtiv, a drug aimed at treating heart failure. His work in characterizing animal models and his in vitro expertise have been critical in advancing these therapeutic innovations.
Experience in Training and Leadership
Chris Zambataro has a proven track record in training junior scientists and technical staff. His emphasis on detailed and reproducible science ensures high standards in research practices. Furthermore, he has led multiple sarcomere discovery projects, focusing on both inherited and acquired diseases, underlining his leadership capabilities in advancing scientific research.